These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31425802)

  • 1. Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI.
    Moon WK; Chen HH; Shin SU; Han W; Chang RF
    Magn Reson Imaging; 2019 Nov; 63():60-69. PubMed ID: 31425802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
    Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasonic Features and Molecular Subtype Predict Somatic Mutations in TP53 and PIK3CA Genes in Breast Cancer.
    Huang Y; Qiang Y; Jian L; Jin Z; Lang Q; Sheng C; Shichong Z; Cai C
    Acad Radiol; 2022 Dec; 29(12):e261-e270. PubMed ID: 35450798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
    Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
    Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
    Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
    Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
    Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
    Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.
    Li G; Guo X; Chen M; Tang L; Jiang H; Day JX; Xie Y; Peng L; Xu X; Li J; Wang S; Xiao Z; Dai L; Wang J
    PLoS One; 2018; 13(9):e0203495. PubMed ID: 30212483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
    Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
    Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation profiling in the PIK3CA, TP53, and CDKN2A genes in circulating free DNA and impalpable breast lesions.
    Delmonico L; Costa MASM; Fournier MV; Romano SO; Nascimento CMD; Barbosa AS; Moreira ADS; Scherrer LR; Ornellas MHF; Alves G
    Ann Diagn Pathol; 2019 Apr; 39():30-35. PubMed ID: 30634138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
    Park JH; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim D; Kim SB
    Anticancer Res; 2020 Oct; 40(10):5883-5893. PubMed ID: 32988919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of ESR1 Germline Variants with TP53 Somatic Variants in Breast Tumors in a Genome-wide Study.
    Tjader NP; Beer AJ; Ramroop J; Tai MC; Ping J; Gandhi T; Dauch C; Neuhausen SL; Ziv E; Sotelo N; Ghanekar S; Meadows O; Paredes M; Gillespie JL; Aeilts AM; Hampel H; Zheng W; Jia G; Hu Q; Wei L; Liu S; Ambrosone CB; Palmer JR; Carpten JD; Yao S; Stevens P; Ho WK; Pan JW; Fadda P; Huo D; Teo SH; McElroy JP; Toland AE
    Cancer Res Commun; 2024 Jun; 4(6):1597-1608. PubMed ID: 38836758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of TP53 and PIK3CA mutations analyzed by next-generation sequencing in breast cancer.
    Choi JH; Yu J; Jung M; Jekal J; Kim KS; Jung SU
    Medicine (Baltimore); 2023 Sep; 102(38):e35267. PubMed ID: 37747019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
    Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
    Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast.
    Bataillon G; Fuhrmann L; Girard E; Menet E; Laé M; Capovilla M; Treilleux I; Arnould L; Penault-Llorca F; Rouzier R; Marchiò C; Bieche I; Vincent-Salomon A
    Histopathology; 2018 Aug; 73(2):273-283. PubMed ID: 29537649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
    Chen TW; Hsiao W; Dai MS; Lin CH; Chang DY; Chen IC; Wang MY; Chang SH; Huang SM; Cheng AL; Wu KW; Tan KT; Lu YS
    Breast Cancer Res Treat; 2023 Oct; 201(3):377-385. PubMed ID: 37344660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
    Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
    Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRI.
    Chang RF; Chen HH; Chang YC; Huang CS; Chen JH; Lo CM
    Magn Reson Imaging; 2016 Jul; 34(6):809-819. PubMed ID: 26968141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer.
    Jiang YZ; Yu KD; Bao J; Peng WT; Shao ZM
    Cancer Res; 2014 Jul; 74(13):3399-407. PubMed ID: 24924774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity.
    Croessmann S; Wong HY; Zabransky DJ; Chu D; Rosen DM; Cidado J; Cochran RL; Dalton WB; Erlanger B; Cravero K; Button B; Kyker-Snowman K; Hurley PJ; Lauring J; Park BH
    Breast Cancer Res Treat; 2017 Apr; 162(3):451-464. PubMed ID: 28190247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.